| DB ID | MyCo_3033 |
| Title | Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis |
| Year | 2008 |
| PMID | 18779361 |
| Fungal Diseases involved | Hematogenous Candida meningoencephalitis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | They were monitored under human care and use standards in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, according to the guidelines of the Na- tional Research Council for the care and use of laboratory animals and under the approval of the Animal Care and Use Committee of the National Cancer Insti-tute. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Plasma |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Predictive-surrogate |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Female New Zealand White rabbits (Covance Research Products, Inc., Denver, PA) weighing 2.4 to 3.7 kg at the time of intravenous candidal challenge were used in all experiments of the nonneutropenic rabbit model of experimental HCME. All rabbits (n=119) were individually housed and maintained with water and standard rabbit feed ad libitum. |
| Cohort No. | 119 |
| Age Group | None |
| P Value | p<0.05 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Hematogenous Candida meningoencephalitis (HCME) is a common complication of candidemia in pediatric patients, par- ticularly premature neonates. Neonatal HCME results in significant morbidity, including mental retardation, seizures, and adverse neurological outcomes. Recent studies show that central nervous system (CNS) infection caused by Candida spp. occurs more often than is detected by positive blood and/or cerebrospinal fluid (CSF) cultures. Currently, there are relatively few options for the treat-ment of HCME. The use of amphotericin B deoxycholate, despite its broad-spectrum antifungal activity and demon- strated efficacy, is often limited by drug-related nephrotoxicityas well as poor penetration of the blood-brain barrier. There is anurgent requirement for better diagnostic tools as well as more-efficacious and less-toxic antifungal therapies. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
